Novo Loses Brazil Share to Generics
Novo Nordisk is losing market share in Brazil following the expiration of its semaglutide patent, leading to a sales decline in emerging markets. However, the drugmaker has largely maintained its position in Canada and India against lower-priced rivals.
Xurve View
Perspectivas:
Xurve View
NOVO NORDISK A/S-B posted a 3% decline in emerging market sales during the third quarter after losing market share in Brazil to cheaper generics. The drop followed the expiration of patents for semaglutide, the active ingredient in the company's flagship treatments.
